GlassScriptPhysician profile
Jodi K Padgett
NPI 1588786537
$1,380.98
in general payments reported to CMS, 2019-2025
18 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $320 · 2023: $265 · 2024: $210 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $246.88 | 2022-2024 | Shingrix, Bexsero, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.88 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $134.36 | 2021-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $124.56 | 2021 | |
| Lilly USA, LLC | $115.78 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $92.42 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $79.14 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $68.48 | 2021-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $67.79 | 2022-2023 | |
| Myriad Women'S Health, INC. | $61.58 | 2023 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $53.23 | 2021-2025 | Farxiga |
| Insulet Corporation | $46.57 | 2025 | Omnipod |
| Amgen INC. | $37.42 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.23 | 2022-2025 | Xifaxan |
| Lundbeck LLC | $31.69 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.51 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2025 | |
| Boston Scientific Corporation | $14.02 | 2024 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Padgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.